您的瑞士法律团队 – 日内瓦新办公室

27 八月 2019

Biognosys, a Swiss proteomics company, continues realizing its ambition to enable clinical researchers to directly measure and quantify thousands of proteins from patient tissues in clinical trials by offering its next-generation label-free proteomics technology. To accelerate this development, the company has raised new funds in Series G financing round.The financing round includes a new industrial investor, in addition to existing institutional and private shareholders. VISCHER AG advised Biognosys, the team was led by Matthias Staehelin with Dania Salvisberg and Sebastian Flückiger (all Corporate).

Press release Biognosys

Categories: 生命科学、医药、生物技术, 私募股权、风险投资、企业融资

You are currently offline. Some pages or content may fail to load.